AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8053584 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sufentanil infusion at 0.2 microgram.kg‐1.h‐1
Number of subjects: 50
Study 2927302 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymers (3 g.kg‐1 in a 50% solution)
Number of subjects: 6
Study 2927302 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificially sweetened)
Number of subjects: 6
Study 31743467 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA air cleaner
Number of subjects: 43
Study 31743467 — intervention group
Group type: COMPARATOR
Intervention: Placebo 'dummy' treatment
Number of subjects: 43
Study 31815656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention via online multimedia video game with smartphone app companion
Number of subjects: 548
Study 31815656 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving online information on active aging
Number of subjects: 548
Study 28576675 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib plus fulvestrant
Number of subjects: 1147
Study 28576675 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 1147
Study 28576675 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib
Number of subjects: 1147
Study 28576675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1147
Study 26423375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led palliative care intervention (assessments of physical, emotional, and spiritual wellbeing and quality of life) given six times over 4 months.
Number of subjects: 120
Study 26423375 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 120
Study 23859389 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling ketamine 1 mg/kg (Group Ki)
Number of subjects: 90
Study 23859389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ketamine 1 mg/kg (Group Kv)
Number of subjects: 90
Study 23859389 — intervention group
Group type: COMPARATOR
Intervention: Inhaling normal saline 10 ml (Group C)
Number of subjects: 90
Study 22585697 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofarabine plus cytarabine (Clo+Ara‐C arm)
Number of subjects: 320
Study 22585697 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine (Ara‐C arm)
Number of subjects: 320
Study 18534440 — intervention group
Group type: EXPERIMENTAL
Intervention: Rim cutter
Number of subjects: 40
Study 17103207 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual imagery task
Number of subjects: 30
Study 17103207 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile imagery task
Number of subjects: 30
Study 17103207 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental computation task
Number of subjects: 30
Study 17103207 — intervention group
Group type: COMPARATOR
Intervention: Cognitive tasks (visual and tactile imagery)
Number of subjects: 30
Study 15961421 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity‐dependent force field (VF) introduced for sets of three consecutive trials.
Number of subjects: 0
Study 12354090 — intervention group
Group type: EXPERIMENTAL
Intervention: New toothbrush
Number of subjects: 40
Study 12354090 — intervention group
Group type: COMPARATOR
Intervention: 3-month-old toothbrush
Number of subjects: 40
Study 10400422 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA (All-Trans Retinoic Acid)
Number of subjects: 0
Study 10400422 — intervention group
Group type: EXPERIMENTAL
Intervention: As2O3 (Arsenic Trioxide)
Number of subjects: 0
Study 10400422 — intervention group
Group type: COMPARATOR
Intervention: DNR (Daunorubicin)
Number of subjects: 0
Study 7549366 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 3 micrograms/kg 10 min before induction
Number of subjects: 24
Study 7549366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2044734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bricanyl Turbuhaler (dry powder terbutaline 0.5 mg q.i.d)
Number of subjects: 258
Study 2044734 — intervention group
Group type: COMPARATOR
Intervention: Bricanyl metered dose inhaler (MDI) (terbutaline 0.5 mg q.i.d)
Number of subjects: 258
Study 6166799 — intervention group
Group type: EXPERIMENTAL
Intervention: Suloctidil
Number of subjects: 45
Study 6166799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 6166799 — intervention group
Group type: EXPERIMENTAL
Intervention: Suloctidil and Placebo
Number of subjects: 45
Study 31330899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D + Phenylbutyrate
Number of subjects: 167
Study 29099626 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG)
Number of subjects: 250
Study 29099626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMBG)
Number of subjects: 250
Study 29099626 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured SMBG
Number of subjects: 250
Study 25958709 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics discontinued promptly after CRP level < 10 mg/L in group Ia
Number of subjects: 98
Study 25958709 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics continued until all bacterial cultures were negative in group Ib
Number of subjects: 98
Study 25958709 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics continued until CRP < 10 mg/L in group IIa
Number of subjects: 98
Study 25958709 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics continued until all bacterial cultures were negative in group IIb
Number of subjects: 98
Study 23587364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention consisting of 7 individual nutrition consulting sessions (approximately 60 minutes each) delivered by an Accredited Practising Dietitian (APD) focusing on a healthy diet based on the Australian Dietary Guidelines and the Dietary Guidelines for Adults in Greece.
Number of subjects: 176
Study 23587364 — intervention group
Group type: COMPARATOR
Intervention: Social support group (befriending protocol) with the same visit schedule and length as the diet intervention.
Number of subjects: 176
Study 21978220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 32
Study 19857666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) C(0) levels below 1.0 to 1.5 microg/mL at day 7
Number of subjects: 42
Study 19857666 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA C(0) levels
Number of subjects: 42
Study 19857666 — intervention group
Group type: EXPERIMENTAL
Intervention: MPAG C(0) levels above 100 to 150 microg/mL at day 7
Number of subjects: 42
Study 19857666 — intervention group
Group type: EXPERIMENTAL
Intervention: MPAG C(0) levels
Number of subjects: 42
Study 17098132 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (graded supine bicycle exercise at 25 W and 50 W)
Number of subjects: 40
Study 17098132 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 40
Study 15113721 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg Zn)
Number of subjects: 242
Study 15113721 — intervention group
Group type: COMPARATOR
Intervention: Control group (without zinc supplementation)
Number of subjects: 242
Study 11340212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 75
Study 9117505 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational workshops (single-session)
Number of subjects: 132
Study 9117505 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop attendance
Number of subjects: 132
Study 7913986 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) administered antenatally, intrapartum, and postnatally
Number of subjects: 0
Study 2970000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CA)
Number of subjects: 10
Study 2970000 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (F)
Number of subjects: 10
Study 2970000 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 10
Study 30175904 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application intervention for online social networking addiction
Number of subjects: 200
Study 30175904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 28095892 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuna manual therapy
Number of subjects: 60
Study 28095892 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 28095892 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuna plus usual care
Number of subjects: 60
Study 25432081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 5 mg/ml instilled 3 times daily (n = 72)
Number of subjects: 510
Study 25432081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 5 mg/ml instilled 4 times daily (n = 74)
Number of subjects: 510
Study 25432081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 10 mg/ml instilled 2 times daily (n = 73)
Number of subjects: 510
Study 25432081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 10 mg/ml instilled 3 times daily (n = 73)
Number of subjects: 510
Study 25432081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 10 mg/ml instilled 4 times daily (n = 72)
Number of subjects: 510
Study 25432081 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab injection administered once every 4 weeks (n = 73)
Number of subjects: 510
Study 25432081 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops instilled 4 times daily (n = 73)
Number of subjects: 510
Study 23480247 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 0
Study 21498494 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal morphine 100 µg + TAP block with bupivacaine 2 mg kg(‐1) (S(M)T(LA))
Number of subjects: 80
Study 21498494 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal morphine 100 µg + TAP block with saline (S(M)T(S))
Number of subjects: 80
Study 21498494 — intervention group
Group type: COMPARATOR
Intervention: Saline + TAP block with saline (S(S)T(S))
Number of subjects: 80
Study 21498494 — intervention group
Group type: COMPARATOR
Intervention: Saline + TAP block with bupivacaine (S(S)T(LA))
Number of subjects: 80
Study 19468030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-Intensive Epirubicin and Cyclophosphamide (DI-EC)
Number of subjects: 344
Study 19468030 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Chemotherapy (SD-CT)
Number of subjects: 344
Study 16760197 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg Methylphenidate (MPH)
Number of subjects: 16
Study 16760197 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg Atomoxetine (ATX)
Number of subjects: 16
Study 16760197 — intervention group
Group type: COMPARATOR
Intervention: Both MPH and ATX
Number of subjects: 16
Study 15325327 — intervention group
Group type: EXPERIMENTAL
Intervention: GRIF system (automated test ordering and feedback system)
Number of subjects: 11
Study 11771637 — intervention group
Group type: EXPERIMENTAL
Intervention: Black confederates present during the event (experimental condition)
Number of subjects: 0
Study 11771637 — intervention group
Group type: COMPARATOR
Intervention: White confederates present during the event (control)
Number of subjects: 0
Study 9483720 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation ratio model applied to individual responses in a seasonal rhinitis trial.
Number of subjects: 0
Study 9483720 — intervention group
Group type: EXPERIMENTAL
Intervention: Markov chain approach for dependence on previous responses.
Number of subjects: 0
Study 8287660 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine
Number of subjects: 28
Study 3162653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan plus doxycycline
Number of subjects: 68
Study 3162653 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin plus doxycycline
Number of subjects: 68
Study 31425478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment (0.5 mg in 0.05 ml via six intravitreal injections over 6 months)
Number of subjects: 7
Study 31425478 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological analysis
Number of subjects: 7
Study 31425478 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Number of subjects: 7
Study 31383445 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Number of subjects: 90
Study 31383445 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with orange essential oil
Number of subjects: 90
Study 31383445 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 90
Study 31383445 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between lavender and orange essential oil
Number of subjects: 90
Study 28104706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignettes without a risk score
Number of subjects: 129
Study 28104706 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignettes with a risk score
Number of subjects: 129
Study 26396095 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol alone
Number of subjects: 66
Study 26396095 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol plus calcium carbonate
Number of subjects: 66
Study 26396095 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate alone
Number of subjects: 66
Study 24575644 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal atrial fibrillation group
Number of subjects: 20
Study 24575644 — intervention group
Group type: COMPARATOR
Intervention: Control group (without AF, with premature ventricular ectopic beats)
Number of subjects: 20
Study 21237502 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg, two tablets once daily)
Number of subjects: 129
Study 21237502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 18083770 — intervention group
Group type: COMPARATOR
Intervention: Conventional tidal volume (V(T)) of 12 ml/kg without positive end-expiratory pressure (PEEP)
Number of subjects: 40
Study 18083770 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume (V(T)) of 6 ml/kg and 10 cmH(2)O PEEP
Number of subjects: 40
Study 16202482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling epsilon4 carriers
Number of subjects: 71
Study 16202482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling non-epsilon4 carriers
Number of subjects: 71
Study 16202482 — intervention group
Group type: COMPARATOR
Intervention: Control epsilon4 carriers
Number of subjects: 71
Study 15454803 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin concentration, 70 g/L)
Number of subjects: 203
Study 15454803 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin concentration, 100 g/L)
Number of subjects: 203
Study 15454803 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 203
Study 15454803 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 203
Study 11688554 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Nonspi 5R = Np)
Number of subjects: 21
Study 11688554 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (ViskenR = Vs)
Number of subjects: 21
Study 11688554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of pindolol
Number of subjects: 21
Study 8660040 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium‐99m‐HMPAO labelled white cell scan (Tc‐WCS)
Number of subjects: 39
Study 8660040 — intervention group
Group type: COMPARATOR
Intervention: Barium follow through examination (Ba‐FT)
Number of subjects: 39
Study 8660040 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy plus biopsy
Number of subjects: 39
Study 1516333 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic balls (Protasul-2)
Number of subjects: 0
Study 1516333 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic balls (Prostasul-10)
Number of subjects: 0
Study 1516333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic balls
Number of subjects: 0
Study 6643396 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lorazepam (2 mg)
Number of subjects: 6
Study 6643396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31567166 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Definition Chromoendoscopy with targeted biopsy (HDCE-T)
Number of subjects: 210
Study 31567166 — intervention group
Group type: COMPARATOR
Intervention: High-Definition White Light Endoscopy with random biopsy (HDWL-R)
Number of subjects: 210
Study 28796416 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir
Number of subjects: 0
Study 25155750 — intervention group
Group type: EXPERIMENTAL
Intervention: PSAA+PNB
Number of subjects: 331
Study 25155750 — intervention group
Group type: COMPARATOR
Intervention: PNB
Number of subjects: 331
Study 22106853 — intervention group
Group type: COMPARATOR
Intervention: OROS MPH 72 mg/day
Number of subjects: 279
Study 22106853 — intervention group
Group type: COMPARATOR
Intervention: OROS MPH 54 mg/day
Number of subjects: 279
Study 22106853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 21501093 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiCor(®) (EP) 500 mg
Number of subjects: 12
Study 21501093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19664653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (screening for ischemic heart disease and advice for healthier lifestyle)
Number of subjects: 9322
Study 19664653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 9322
Study 19664653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9322
Study 17874825 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg polaprezinc (zinc group)
Number of subjects: 23
Study 17874825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 23
Study 15095954 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal nasal positive pressure ventilation (NNPPV)
Number of subjects: 27
Study 11520252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent Hib-HB vaccine with DTP, OPV or IPV, DTaP, M-M-R(II)
Number of subjects: 126
Study 9611360 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 43
Study 9611360 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 43
Study 7635034 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay‐Bayer)
Number of subjects: 0
Study 7635034 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral therapy
Number of subjects: 0
Study 3289583 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gentamicin solution
Number of subjects: 102
Study 3289583 — intervention group
Group type: COMPARATOR
Intervention: Control (no gentamicin)
Number of subjects: 102
Study 31394015 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐122 (n = 17)
Number of subjects: 69
Study 31394015 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐48 (n = 14)
Number of subjects: 69
Study 31394015 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐122 and TJ‐48 (n = 19)
Number of subjects: 69
Study 31394015 — intervention group
Group type: COMPARATOR
Intervention: No traditional medicines (n = 19)
Number of subjects: 69
Study 28288833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group (n=20)
Number of subjects: 75
Study 28288833 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake group (n=17)
Number of subjects: 75
Study 28288833 — intervention group
Group type: COMPARATOR
Intervention: Immediate Test control groups (n=36 total, n=18 each)
Number of subjects: 75
Study 26105600 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg once daily until progression/unacceptable toxicity)
Number of subjects: 217
Study 26105600 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GP) [G 1250 mg/m(2) i.v. days 1 and 8 (3-weekly cycle); P 75 mg/m(2) i.v. day 1, (3-weekly cycle) for up to four cycles]
Number of subjects: 217
Study 26105600 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 217
Study 26105600 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GP)
Number of subjects: 217
Study 23679567 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of e-mental health information by text
Number of subjects: 217
Study 23679567 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of e-mental health information by film
Number of subjects: 217
Study 23679567 — intervention group
Group type: COMPARATOR
Intervention: Provision of no e-mental health information
Number of subjects: 217
Study 21946486 — intervention group
Group type: EXPERIMENTAL
Intervention: M-Bond (MB)
Number of subjects: 0
Study 21946486 — intervention group
Group type: EXPERIMENTAL
Intervention: M-Bond II (MB II)
Number of subjects: 0
Study 21946486 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-Bond C&B (SB)
Number of subjects: 0
Study 19339531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed margins
Number of subjects: 66
Study 19339531 — intervention group
Group type: EXPERIMENTAL
Intervention: Refurbishment
Number of subjects: 66
Study 19339531 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair
Number of subjects: 66
Study 19339531 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement
Number of subjects: 66
Study 19339531 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 66
Study 16353141 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer using PSA tests during the 1st visit
Number of subjects: 58710
Study 16353141 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer using PSA tests during the 2nd visit
Number of subjects: 58710
Study 16353141 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall detection rate of high-grade cancers during the 1st visit
Number of subjects: 58710
Study 16353141 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall detection rate of high-grade cancers during the 2nd visit
Number of subjects: 58710
Study 15189589 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological-state theories (PSTs) about significant others
Number of subjects: 0